Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors

NCT04908176 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.

NCT NCT04908176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04908176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Drug-drug Interaction Study to Investigate the Effect of Avapritinib on the Pharmacokinetics of Midazolam in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) and Other Advanced Solid Tumors
Lead sponsor
Blueprint Medicines Corporation
Phase
Phase 1
Overall status
Completed
Start date
August 24, 2022
Completion date
May 10, 2024
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal stromal tumors, gist, non-resectable advanced solid tumors, recurrent or unresectable central nervous system (cns) tumors